EHA 2018 | How should MRD be used for MM in routine clinical practice?
Bruno Paiva
• 14 Jun 2018
There are currently no concrete guidelines for how to use measurable residual disease (MRD) status to inform treatment decisions in multiple myeloma (MM). In this video, recorded at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, gives his opinion on how MRD should be utilized in routine clinical practice for MM. Dr Paiva emphasizes the use of MRD as one of a suite of diagnostic and prognostic tests that should be carried out, saying it should be used to inform clinicians’ overall understanding of a patient’s disease and treatment.
